TrialPloS one2013

Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.

Andrew R Moore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.